FOLLOWING its decision to keep
the controversial diabetes pill,
Avandia, on the US market (PD 15
Jul), the Food and Drug Authority
has called a halt to a current
comparative study of the safety of
Avandia and its competitor, Actos.
The above snippet is the first part of an article sent to subscribers in Pharmacy Daily's issue from 22 Jul 10
To see the full story, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 22 Jul 10
